Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2014
Summary
Global Markets Direct’s, ‘Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2014’, provides an overview of the Genital Warts (Condylomata Acuminata)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Genital Warts (Condylomata Acuminata)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Genital Warts (Condylomata Acuminata) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Genital Warts (Condylomata Acuminata) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Genital Warts (Condylomata Acuminata) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Genital Warts (Condylomata Acuminata)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Genital Warts (Condylomata Acuminata) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Genital Warts (Condylomata Acuminata) Overview 6
Therapeutics Development 7
Pipeline Products for Genital Warts (Condylomata Acuminata) - Overview 7
Pipeline Products for Genital Warts (Condylomata Acuminata) - Comparative Analysis 8
Genital Warts (Condylomata Acuminata) - Therapeutics under Development by Companies 9
Genital Warts (Condylomata Acuminata) - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Genital Warts (Condylomata Acuminata) - Products under Development by Companies 12
Genital Warts (Condylomata Acuminata) - Companies Involved in Therapeutics Development 13
Agilvax, Inc. 13
Anaconda Pharma 14
BioMAS Ltd. 15
Foamix Pharmaceuticals Ltd. 16
G&E Herbal Biotechnology Co., Ltd. 17
Helix BioPharma Corp. 18
NanoViricides, Inc. 19
Genital Warts (Condylomata Acuminata) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AP-611074 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AS-101 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AX-03 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
HerpeCide-I - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
imiquimod - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
interferon alpha-2b (recombinant) - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PP-210 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SRT-100 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Genital Warts (Condylomata Acuminata) - Recent Pipeline Updates 39
Genital Warts (Condylomata Acuminata) - Dormant Projects 41
Genital Warts (Condylomata Acuminata) - Discontinued Products 42
Genital Warts (Condylomata Acuminata) - Product Development Milestones 43
Featured News & Press Releases 43
Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions 43
Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 44
Mar 22, 2010: Helix BioPharma Corp Achieves Last-Patient-Out In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts 44
Sep 22, 2008: Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47
List Of Tables
List of Tables
Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2014 7
Number of Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Genital Warts (Condylomata Acuminata) - Pipeline by Agilvax, Inc., H2 2014 13
Genital Warts (Condylomata Acuminata) - Pipeline by Anaconda Pharma, H2 2014 14
Genital Warts (Condylomata Acuminata) - Pipeline by BioMAS Ltd., H2 2014 15
Genital Warts (Condylomata Acuminata) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2014 16
Genital Warts (Condylomata Acuminata) - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2014 17
Genital Warts (Condylomata Acuminata) - Pipeline by Helix BioPharma Corp., H2 2014 18
Genital Warts (Condylomata Acuminata) - Pipeline by NanoViricides, Inc., H2 2014 19
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 26
Number of Products by Stage and Molecule Type, H2 2014 28
Genital Warts (Condylomata Acuminata) Therapeutics - Recent Pipeline Updates, H2 2014 39
Genital Warts (Condylomata Acuminata) - Dormant Projects, H2 2014 41
Genital Warts (Condylomata Acuminata) - Discontinued Products, H2 2014 42
List Of Figures
List of Figures
Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2014 7
Number of Products under Development for Genital Warts (Condylomata Acuminata) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 20
Number of Products by Top 10 Targets, H2 2014 21
Number of Products by Stage and Top 10 Targets, H2 2014 22
Number of Products by Top 10 Mechanism of Actions, H2 2014 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 24
Number of Products by Top 10 Routes of Administration, H2 2014 25
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 26
Number of Products by Top 10 Molecule Types, H2 2014 27
Number of Products by Stage and Top 10 Molecule Types, H2 2014 28
